Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple blood test help rheumatoid arthritis patients get the right drug?

NCT ID NCT03853395

Knowledge-focused Sponsor: University of Manchester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether measuring drug levels and anti-drug antibodies in the blood of rheumatoid arthritis patients can help doctors make better treatment decisions. 52 patients starting adalimumab or certolizumab were randomly assigned to have their test results shared with their doctor or to receive standard care. The goal was to see if this approach is feasible for a larger trial, not yet to prove it improves outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
drug level and anti-drug antibody tests
What this could lead to
If successful, this could pave the way for a larger trial that proves using these tests helps doctors choose better treatments for rheumatoid arthritis patients.
What could go wrong
This is a small feasibility study, not designed to prove the tests work. The tests are expensive and may not improve patient outcomes in the end.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

52 people

The number who actually took part.

Started

May 2019

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with RA about to start therapy with adalimumab or certolizumab 2. Age 18 and over, male or female 3. Willing to take part in the study 4. Patients who consent to take part in the BRAGGSS study Exclusion Criteria: 1. Patients unwilling or unable to take part in the study 2. Pregnant women or nursing (breast feeding) mothers. 3. Planned pregnancy within next 12 months. 4. Scheduled surgery in the next 12 months or other pre-planned reasons for treatment discontinuation in the next 12 months. 5. Contraindication to adalimumab or certolizumab according to the summary of product characteristics

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthritis rheumatoid are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthritis rheumatoid

Contacts and locations

Locations

  • Centre for Musculoskeletal Research

    Manchester, England, M13 9PT, United Kingdom

  • Hampshire Hospitals NHS Foundation Trust

    Basingstoke, Hampshire, RG24 9NA, United Kingdom

  • Homerton University Hospital NHS Foundation Trust

    London, E9 6SR, United Kingdom

  • Leicester Royal Infirmary

    Leicester, LE1 5WW, United Kingdom

  • Manchester University Hospitals NHS Foundation Trust

    Manchester, M13 9WL, United Kingdom

  • Midlands Partnership NHS Foundation Trust

    Stafford, Staffordshire, ST16 3AG, United Kingdom

  • Northern Care Alliance NHS Group

    Manchester, M5 5AP, United Kingdom

  • Royal Wolverhampton NHS Trust

    Wolverhampton, WV10 0QP, United Kingdom

  • Torbay and South Devon NHS Foundation Trust

    Torquay, TQ2 7AA, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.